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Forty patients with multiple myeloma scheduled to undergo high dose chemotherapy with autologous stem cell support were
randomized in a double blinded fashion to receive adjuvant treatment with the mushroom extract AndoSan, containing 82%
of Agaricus blazei Murrill (19 patients) or placebo (21 patients). Intake of the study product started on the day of stem cell
mobilizing chemotherapy and continued until the end of aplasia after high dose chemotherapy, a period of about seven weeks.
Thirty-three patients were evaluable for all study endpoints, while all 40 included patients were evaluable for survival endpoints.
In the leukapheresis product harvested after stem cell mobilisation, increased percentages of Treg cells and plasmacytoid dendritic
cells were found in patients receiving AndoSan. Also, in this group, a significant increase of serum levels of IL-1ra, IL-5, and IL-
7 at the end of treatment was found. Whole genome microarray showed increased expression of immunoglobulin genes, Killer
Immunoglobulin Receptor (KIR) genes, and HLA genes in the Agaricus group. Furthermore, AndoSan displayed a concentration
dependent antiproliferative effect on mouse myeloma cells in vitro. There were no statistically significant differences in treatment
response, overall survival, and time to new treatment. The study was registered with Clinicaltrials.gov NCT00970021.
1. Introduction
Multiple myeloma is a neoplastic disorder caused by malig-
nant transformation of plasma cells. The main clinical fea-
tures are bone marrow failure, lytic bone lesions, and renal
insufficiency.The age adjusted incidence ofmultiplemyeloma
is 4/100 000 and median age at diagnosis is 70 years [1].
High dose chemotherapywith autologous stem cell support is
standard first line treatment for patients below the age of 65–
70 years, taking into consideration patients’ general condition
and comorbidity [2]. The majority responds well to the
initial treatment, but all patients eventually relapse. In recent
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years, the introduction of three new drugs, thalidomide,
bortezomib, and lenalidomide, has significantly improved the
treatment results, butmultiplemyeloma remains an incurable
disease. In patients below 65 years of age, 10 years survival is
currently estimated to about 30% [3].
Agaricus blazeii Murrill (AbM) is an edible Basid-
iomycetes mushroom, which grows naturally in Piedade
outside Sao Paulo in Brazil. It is widely used locally as
a food supplement and as treatment for various medical
conditions [4]. In the 1960s, AbM was brought to Japan for
industrial cultivation and this became the starting point for
scientific research. The fruiting body of AbM is rich in 𝛽-
glucans, which is a potent stimulant of the innate immune
system. 𝛽-Glucan from AbM has been shown to have an
antitumor effect both in vitro (fibrosarcoma [5], ovarian
cancer [6], hepatocarcinoma [7], and leukemia cells [8])
and in animal models (fibrosarcoma [9], multiple myeloma
[10], and lung cancer [11]). It has therefore been assumed
that the medicinal effect of AbM is mainly due to the
immunostimulatory effect of 𝛽-glucans [12]. Ovarian cancer
patients receiving AbM in addition to chemotherapy were
found to have an improved quality of life and a higher
NK-cell activity than patients receiving only chemotherapy
[13]. Our group has previously performed a number of in
vitro, preclinical, and clinical studies using the commercial
Japanese product, AndoSan, which contains 82% of AbM
together with two other mushrooms, Grifola frondosa and
Hericium erinaceus. An increased production of cytokines
and chemokines was demonstrated after incubation with
AndoSan in cultures with human monocytes, umbilical
vein endothelial cells, and monocyte derived dendritic cells
(MDDC) [14, 15]. Incubation with AndoSan in MDDC
cultures was shown to increase the expression of cell surface
markers associated with activation and antigen presentation
[16, 17]. Furthermore, in an mRNA assay on monocytic cells
incubated with AndoSan, there was an upregulation of genes
related to immune function, in particular in genes connected
with proinflammatory cytokines [18]. In contrast, in patients
with chronic hepatitis C receiving treatment with AndoSan,
genes involved in apoptosis and cell proliferation were found
to be upregulated but not genes related to immune function
[19]. Oral intake of AndoSan was found to have an immuno-
suppressive effect both in healthy volunteers [20] and in
patients with inflammatory bowel disease [21].The reason for
the difference between in vitro and in vivo effect on immune
function may possibly be due to differential absorption from
the gut of substances with immunomodulating effects [20].
An extended search in the Medline and PubMed databases
failed to show any reports of toxic effects of AbM. Also,
herb interaction studies with anAgaricus extract, later named
AndoSan, demonstrated a very low inhibition of cytochrome
P-450 metabolism (less than that for green tea), making
clinically relevant adverse effects unlikely [22].
Based on the data cited above and in vitro experiments
included in this report, showing an antiproliferative effect of
AndoSan on mouse myeloma cells, we decided to investigate
immunomodulating and clinical effects of AndoSan given as
adjuvant therapy to patients with multiple myeloma sched-
uled to undergo high dose chemotherapy with autologous
stem cell support.
2. Materials and Methods
2.1. Study Design. Patients with newly diagnosed multiple
myeloma who had completed induction treatment and were
scheduled to undergo stem cell mobilisation followed by
high dose chemotherapy with autologous stem cell support at
Oslo University Hospital, Norway, were eligible for the study.
The patients received written and oral information about
the study by the treating physician. Upon written consent,
patients were randomized in a double blinded fashion to
receive eitherAndoSanor placebo orally, 60mLdaily, starting
from the day of stem cell mobilisation and continuing until
the end of aplasia after high dose chemotherapy, a period of
approximately seven weeks. Randomisation was performed
by a study nurse drawing an envelope from a preprepared
stack, containing a number from 1 to 50, in a random fashion.
Each number corresponded to an allocated treatment (Agari-
cus or placebo), whichwas determined beforehand by a flip of
a coin and known only to the study nurse. The study product
(Agaricus or placebo) was prepared by the study nurse in
identical dark glass bottles, identified only by the patient’s
study number. Thus, the content of the bottles was known to
the study nurse but was blinded to the patients and the rest of
the hospital staff.
The primary end points were (1) changes in serum levels
of cytokines, chemokines, and growth factors in peripheral
blood, (2) differences in expression levels of genes involved
in immune activation by whole genome assay, bothmeasured
on the day of inclusion and at the end of intake of the
study product, and (3) differences in the stem cell harvest
product of a number of mononuclear cell subsets associated
with the immune system. All biological samples were kept
at −20∘C and analyzed together at the end of the study.
The blinding was unravelled after all laboratory tests had
been performed. The secondary end points were (1) clinical
response to treatment, (2) time in neutropenia, (3) days with
body temperature above 38.0∘C, (4) days with i.v. antibiotics
after stem cell infusion, (5) time to new treatment, (6) overall
survival, and (7) quality of life. The basis for the sample size
(𝑛 = 40) was the results of two earlier studies showing
significant changes in the levels of cytokines in healthy
volunteers (𝑛 = 14) [20] and in patients with ulcerative
colitis (𝑛 = 10) and Crohn’s disease (𝑛 = 11) [21] after
intake of AndoSan. The data were collected by the principal
investigator and stored at a research file at the server of Oslo
University Hospital. The study was approved by the Regional
Committee for Medical and Health Research Ethics (REC
South East). The Norwegian Medicines Agency was notified
of the study according to national regulations.
2.2. Study Product. The commercial mushroom extract
AndoSan, produced by the company ACE Ltd., Japan, and
distributed by Immunopharma AS, Norway, was used as
source of AbM. The extract contains the following Basid-
iomycetes mushrooms: 82.4% of AbM, 14.7% of Hericium
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erinaceus, and 2.9%ofGrifola frondosa. AndoSan is registered
as a food product in Japan, EU, and Norway.
Placebo was water with added color.
2.3. Chemotherapy. Stem cell mobilisation was induced by
cyclophosphamide 2 g/m2 i.v andG-CSF. Stem cell harvesting
by leukapheresis was started when the CD34+ cells in
peripheral blood were >20 × 109/L, that is, on days +10–
+12 after stem cell mobilizing chemotherapy. Aliquots of the
leukapheresis product were kept frozen and analysed by flow
cytometry at the end of the study. High dose chemotherapy
was melphalan 200mg/m2 i.v. on day +2, followed by reinfu-
sion of autologous stem cells on day 0 [23].
2.4. Proliferation Assay. A 3H-thymidine incorporation assay
was performed on MOPC315.BM cells, that is, mouse
myeloma cells [24]. The cells were suspended in RPMI 1640
(Lonza, Verviers, Belgium) supplemented with 10% fetal
bovine serum (Sigma-Aldrich, Diegem, Belgium) and 1%
Penicillin/Streptomycin (Sigma-Aldrich), plated in 96-well
plates (5 × 104/100 𝜇L/well) and cultured for 24 hours at 37∘C
and 5% CO
2
in the presence of different AndoSan concentra-
tions. For the last 16 hours of culture, 0.17𝜇Ci of [Methyl-3H]
thymidine (Perkin Elmer, Zaventem, Belgium) was added
to each well. DNA was harvested on Multiscreen Harvest
Plates (Millipore, Carrightwohill, Cork, Ireland) using Filter
Mate Harvester (Perkin Elmer). Plates were dried for 3-
4 hours before adding 25𝜇L/well of Microscint O (Perkin
Elmer) followed by radioactivity measurement (c.p.m.) with
TopCount NXT Microplate Scintillation Counter (Perkin
Elmer).
2.5. Quantitation of Cytokine Levels. The following cytokine,
chemokine, and growth factor serum levels were measured
at the day of inclusion and 1–3 days after the end of the
intake of AndoSan, using multiplex bead-based sand-
wich immunoassay technology (Bio-Rad Laboratories AB,
Sundbyberg, Sweden), strictly following the manufacturers
instruction: IL-1𝛽, IL-1ra, IL-4, IL-5, IL-6, IL-7, IL-8, IL-13,
Eotaxin, G-CSF, IFN-𝛾, IP 10, MCAF, MP1-𝛼, MP1-𝛽, PDGF,
RANTES, and TNF-𝛼.
2.6. Identification of T-Cell Subsets, NK-Cells, and Dendritic
Cell Subsets in the Leukapheresis Product. The leukaphere-
sis products were suspended in RPMI 1640 medium (Life
Technologies, Carlsbad, CA, USA) supplemented with 10%
fetal calf serum and were analyzed using flow cytometry.
Eight-colour analyses were performed for the identification
of the lymphocyte subsets with the following monoclonal
antibodies: CD2, CD3, CD4, CD5, CD7, CD16, CD25, CD56,
CD45, CD45RA, CD45RO, CD9, CD127, CCR7, andHLA-DR
antigens. All antibodies were purchased fromBDBiosciences
(San Jose´, CA, USA) except for anti-CD8, anti-CD56, and
anti-CD127 which were purchased from Beckman Coulter
(Brea, CA, USA); anti-CCR7 was purchased from R&D
systems (MN, USA) and anti HLA-DR from Biolegend (San
Diego, CA, USA).The Blood Dendritic Cell Enumeration Kit
(Miltenyi Biotech GmbH, Bergish Gladbach, Germany) was
used according to the supplier’s protocol to determine plas-
macytoid dendritic cells, type 1 and type 2 myeloid dendritic
cells. Flow cytometry analysis was performed on the LSR II
instrument (BD Biosciences). Data analysis was performed
using the Flow-Jo software (Tree Star, Ashland, OR, USA).
2.7. Gene Expression Studies. Bone marrow aspirate for gene
expression studies was taken on the day of inclusion and 1–
3 days after end of intake of the study product. Microarray
analyses were performed using the Affymetrix GeneChip
Human Gene 1.0 ST Arrays (Affymetrix, Santa Clara, CA,
USA), which contains more than 28,000 gene transcripts.
150 ng of total RNAwas subjected to AmbionWTExpression
Kit (Ambion/Life Technologies, Carlsbad, CA, U.S.) and
GeneChip WT Terminal Labeling Kit (Affymetrix, Santa
Clara, CA, USA) following the manufacturers’ protocols for
whole genome gene expression analysis.
For comparison of gene expressions, a two-way ANOVA
model was used. All raw intensities of microarray datasets
were quantile normalized [25]. Genes with low expression
variation, that is, maximum to minimum intensity less
than twofold difference, were excluded leaving 7564 genes.
Subsequently, a pair-wise Fisher’s linear discriminant analyse
[26] was used to select the top two percentages of the most
differently expressed genes (i.e., 152 genes) between control
and theAgaricus group.The selected geneswere classified into
four clusters by using K-means clustering algorithm [25]. In
addition, microarray data were analysed through the use of
Ingenuity Pathway Analysis (http://www.ingenuity.com/).
2.8. Clinical Data
2.8.1. Classification. The patients were classified at inclusion
according to the international staging system for multiple
myeloma [27].
Treatment response was assessed by changes in the serum
level of the M-component from start of induction until
three months after high dose chemotherapy according to the
international uniform response criteria [28].
Time to regeneration of neutrophils was the time between
infusion of stem cells and the first day of a stable neutrophil
count of 0.5 ⋅ 109/L or above.
Time to new treatment was the time between inclusion
and start of second line chemotherapy following progression
or follow-up as of July 1, 2014.
Overall survival was the time between inclusion and
follow-up as of July 1, 2014, or death.
2.8.2. Quality of Life. Health related quality of life was meas-
ured at start of the study and threemonths after end of aplasia
using the QLQ-C 30 questionnaire validated for multiple
myeloma [29].
2.9. Statistics. Differences between changes in serum levels
of cytokines, chemokines, and growth factor before and after
treatment in the two treatment groups were calculated by
the Independent Samples t-test on the IBM SPSS Statistics
21 program. The same program was used for calculation of
differences in cell surface expression of leukocyte antigens























Figure 1: Effect of AndoSan on the proliferation of a murine
multiple myeloma cell line in vitro. Proliferation of MOPC315.BM
cells was assessed by 3H-labelled thymidine incorporation in the
presence of different AndoSan concentrations (1.25%–20%). Results
are expressed in percentage of proliferation (mean ± SD) relative
to MOPC315.BM cells cultured without AndoSan (= 100%) and
represent 3 independent experiments. Within each experiment,
proliferation was assessed in triplicate. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and
∗∗∗𝑃 < 0.001 (unpaired Student’s t-test).
in the leukapheresis product. The survival analyses were
performed by the Kaplan-Meier test. Statistical methods used
in gene expression analyses are reported under that section.
3. Results and Discussion
3.1. Myeloma Proliferation Assay. AndoSan significantly in-
hibited the proliferation of MOPC315.BM murine myeloma
cells in vitro at a concentration of 1%.The observed inhibition
was dose dependent (Figure 1).
3.2. Patient Number. From beginning of August 2009 until
end of November 2010, 44 consecutive patients were invited
to participate in the study, and 40 patients accepted. Nineteen
were randomized to the Agaricus group and 21 to the
placebo group. Three patients in the Agaricus group and
four patients in the placebo group later withdrew from the
study. Consequently, the total number of patients completing
the study was 33, 16 in the Agaricus group and 17 in the
placebo group. All included patients were evaluated for
treatment response and survival, except for two patients
with nonsecretory disease in each group who could not be
evaluated for treatment response. Patients’ characteristics are
shown in Table 1. The inclusion was stopped according to
schedule as the stipulated sample size had been reached.
3.3. Cytokines, Chemokines, and Leucocyte Growth Factors. A
significant increase in serum levels of IL-1ra, IL-5, and IL-7
from inclusion until the end of intake of the study product
was observed in theAgaricus group.No significant differences
were seen in any of the other cytokines, chemokines, and
growth factors (Table 2).
3.4. Cell Surface Markers in the Leukapheresis Product. Sig-
nificantly higher percentages of Treg cells (CD4+, CD127d+,
Table 1: The distribution of the patients in the two study groups.
The clinical stage at inclusion according to the International Staging
System [27] is indicated.
(a)





















∗Patients who withdrew from the study.
M/F = 12/7; mean age = 57,4; I = 9, II = 8, and III = 2.
(b)























∗Patients who withdrew from the study.
M/F = 12/6; mean age = 56,6; I = 5, II = 11, and III = 5.
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Table 2: Mean serum levels and range are shown for cytokines, chemokines, and growth factors (in pg/mL) at inclusion and at the end of
intake of study product for the Agaricus (𝑛 = 16) and the placebo group (𝑛 = 17). The statistical relationship of the differences of the means of
the two groups is shown in the column “A/P.”
Agaricus Placebo A/P
Start End Difference Start End Difference 𝑃 value
Mean Mean Mean Mean
IL-1ra 53.21 84.51 31.30 94.79 69.46 −25.33
𝑃 = 0.02
(Range) (7.21–125.52) (21.9–268.37) (21.69–268.37) (6.10–167.65)
IL-4 1.57 2.01 0.44 1.82 1.84 0.02 n.s.
(Range) (0.39–3.31) (0.75–4.17) (0.54–5.27) (0.42–4.97)
IL-5 1.66 2.89 1.23 2.75 2.21 −0.54
𝑃 = 0.05
(Range) (0.02–4.89) (0.19–9.37) (0.36–8.29) (0.43–5.60)
IL-6 4.65 7.71 3.07 9.55 10.39 0.84 n.s.
(Range) (0.03–11.32) (0.88–18.40) (2.29–28.67) (2.60–32.82)
IL-7 4.77 6.91 2.12 6.52 6.12 −0.40
𝑃 = 0.05
(Range) (1.37–8.30) (2.61–14.06) (2.09–10.41) (2.34–13.18)
IL-8 12.59 15.14 2.54 13.49 15.41 1.91 n.s.
(Range) (4.13–27.89) (6.82–48.34) (5.74–26.00) (6.10–38.79)
IL-13 5.58 5.98 0.40 6.78 9.27 2.49 n.s.
(Range) (0.87–20.94) (0.02–13.45) (0.87–12.48) (0.87–39.33)
Eotaxine 93.11 105.31 12.20 162.33 112.39 −49.94 n.s.
(Range) (0.11–247.02) (16.59–229.25) (23.02–600.07) (11.00–368.73)
G-CSF 19.06 21.94 2.89 22.34 19.54 −2.79 n.s.
(Range) (5.60–41.66) (9.63–38.64) (9.99–34.41) (7.82–33.92)
gammaIFN 55.41 75.36 19.96 65.69 62.06 −3.62 n.s.
(Range) (3.24–179.72) (17.25–161.35) (13.32–205.88) (1.64–156.12)
IP10 3198.89 3647.61 448.71 3230.03 3677.51 447.40 n.s.
(Range) (1047.70–8564.00) (391.37–12899.26) (562.41–9314.66) (277.79–13636.42)
MCAF 63.73 43.46 −19.27 50.17 43.98 −6.20 n.s.
(Range) (8.14–236.81) (13.89–97.58) (15.37–90.94) (19.88–134.84)
MIPa 50.46 42.48 −7.98 62.87 46.69 −16.16 n.s.
(Range) (28.88–71.61) (21.56–84.55) (17.66–238.61) (21.73–79.61)
PDGF 426.31 450.75 24.44 454.23 158.52 −295.71 n.s.
(Range) (75.90–1327.12) (19.06–3841.38) (45.84–1632.87) (20.99–309.16)
RANTES 10217.89 7497.97 −2719.93 6496.38 4672.52 −1823.86 n.s.
(1846.39–30848.81) (1595.65–29043.80) (644.32–23964.69) (119.20–10435.40)
TNF alpha 6.29 12.35 6.07 10.52 12.05 1.53 n.s.
(0.97–21.66) (0.22–42.11) (0.97–41.87) (0.22–50.85)
andCD25+) and plasmacytoid dendritic cells (CD303+) were
noted in the Agaricus group compared to the placebo group
(Table 3).
3.5. Gene Expression Studies. Gene expression studies were
performed for eight patients in the Agaricus group and six
patients in the placebo group at the time of inclusion and at
the end of study. The selected differentially expressed genes
were grouped in four clusters using K-means clustering algo-
rithm. In cluster three are located several immunoglobulin
related genes (IGKC, IgHV4-31, and IGKC) and genes related
to Natural Killer cells, that is, Killer Immunoglobulin Recep-
tors (KIR2DL3 and KIR2DL4). A low level of expression was
noted for these genes in the control group and a high level
of expression was shown in the Agaricus group (Figure 3).
The Ingenuity system for phenotype-specific clustering of
genes demonstrated upregulation of endosomatic HLA genes
(Figure 4) and the plasmamembraneCD86 gene (not shown)
in the Agaricus group relative to the placebo group. Further-
more, this analysis showed a downregulation of IL-7 and
CCL2 (MCP-1) genes in theAgaricus group relative to placebo
group, whereas expression of IL-5 gene was unaltered (data
not shown).
The records from the gene expression studies are regis-
tered in GEO (record number GSE 60869).
3.6. Treatment Responses. Treatment response could not be
formally evaluated in two patients in each group because of
6 BioMed Research International
Table 3: T-lymphocyte subsets and dendritic cell subsets.
Agaricus (𝑛 = 16) Placebo (=17)
𝑃 value
Mean Range Mean Range
% of T-lymphocytes
CD3+ T cells 86.2 (58.9–94.2) 86.7 (71.7–95.3) n.s.
CD4+ T cells 50.8 (20.0–80.4) 51.8 (7.10–73.6) n.s.
CD8+ T cells 40.4 (10.9–67.9) 39.6 (15.7–83.3) n.s.
% of CD4+ T cells
Naive (CD45RA+/CD27+) 24.7 (5.5–64.0) 29 (8.8–51.4) n.s.
Central memory
(CD45RA−/CD27+) 40.8 (20.3–72.3) 46.7 (30.0–73.5) n.s.
Effector memory
(CD45RA−/CD27−) 19.2 (3.1–37.2) 21.8 (5.5–38.8) n.s
Terminally differentiated memory
(CD45RA+/CD27−) 6 (0.3–38.5) 3.1 (0.2–9.4) n.s
T reg = (CD4+/CD127d+/Cd25+) 11.8 (4.5–18.2) 9 (4.0–17.8) 𝑃 = 0.04
HLA-DR+ CD4+ 29.6 (13.4–55.7) 26.6 (7.9–55.0) n.s
% of CD8+ T cells
Naive (CD45RA+/CD27+) 27.8 (2.4–69.9) 31.4 (5.9–62.5) n.s
Central memory
(CD45RA−/CD27+) 17.3 (1.5–32.8) 20.1 (3.2–43.5) n.s.
Effector memory
(CD45RA−/CD27−) 22.9 (4.4–51.7) 16.8 (4.6–49.3) n.s.
Terminally differentiated memory
(CD45RA+/CD27−) 32.8 (1.4–55.7) 31.7 (5.4–79.0) n.s
HLA-DR+ CD8+ 39.1 (7.5–71.6) 36.2 (5.9–69.3) n.s
Others
%NK cells
(CD2 or CD7+ CD3−) 8.4 (0.9–35.8) 6.7 (1.7–26.7) n.s.
% CD56b+ 9.3 (0.7–35.5) 10.7 (0.1–32.7) n.s.
% CD56b+ CD16+ 70.6 (42.2–94.0) 69.4 (39.9–95.5) n.s.
%CD56−CD16+ 6.4 (0.1–34.1) 2.6 (0.1–15.3) n.s.
%CD94+ 65.5 (25.9–96.4) 60.8 (22.1–84.7) n.s.
% of all cells except for CD14+ monocytes and CD19+
cells
BDCA1 (CD1c+) 0.6 (1.0–1.3) 0.6 (0.1–2.4) n.s.
BDCA2 (CD303) 1.1 (0.2–2.3) 0.7 (0.1–1.4) 𝑃 = 0.04
BDCA3 (CD141) 0.1 (0.04–0.4) 0.1 (0.03–0.3) n.s.
The respective cell populations are given as frequencies of the cellpopulation to which it is a subset: T-cells and NK-cells as percentage of total lymphocytes;
the major T-cell subsets (including CD4 positive, CD8 positive, and CD4/CD8 double negative or double positive); and NK cell subsets (including CD94
positive, CD94 positive, CD56 bright positive, CD56 positive, Cd16 positive, and CD16 positive) as percentages of total T-cells and NK-cells, respectively:
naive, central memory, effector memory, and terminally differentiated memory T-cells as well as CD4 positive T regulatory T-cells of CD4 and CD8 positive
T-cells, respectively. The dendritic cell populations are determined within total cells excluding the CD14 positive and CD19 positive cells.
nonsecretory disease. At inclusion, in theAgaricus group, 8/17
patients had reached at least partial remission after induction
treatment, while the corresponding figure in the placebo
group was 10/19. At the end of study, 16/17 patients in the
Agaricus group and 18/19 patients in the placebo group had
reached at least partial response.
Median time to regeneration of neutrophils was 14.2 days
in the Agaricus group and 13.9 in the placebo group (n.s.).
Days with temperature above 38.0∘C were 3.5 in the
Agaricus group and 3.6 in the placebo group (n.s).
Days with i.v. antibiotics were 8.6 in the Agaricus group
and 10.0 in the placebo group (n.s).
Health related quality of life assessment revealed no differ-
ences between the study groups (data not shown).
3.7. Survival. At follow-up, 11/19 patients in the Agaricus
group and 16/21 patients in the placebo group had started
new treatment. In the placebo group, both patients with
nonsecretory disease had started new treatment, whereas one
of the two patients with nonsecretory disease in the Agaricus















Figure 2: Time to new treatment. Mean time to new treatment in
the Agaricus group (𝑛 = 19) was 37.3 months (upper (blue) curve)
and in the placebo group (𝑛 = 21) 31.4months (lower (green) curve)























Figure 3: Gene expression analysis. K-means clustering algo-
rithm. Cluster three. Several immunoglobulin related genes (IGKC,
IgHV4-31, and IGKC) and genes related toNatural Killer cells, Killer
Immunoglobulin Receptors (KIR2DL3 and KIR2DL4), are grouped
together. These genes are more highly expressed in the Agaricus
group (left column).
group had not. Mean time to new treatment was 37.3 months
in the Agaricus group and 31.4 months in the placebo group
(𝑃 = 0.49). Median observation time was 29.5 months
(Figure 2) (𝑛 = 40).
At the same time point, 13/19 patients in the Agaricus
group and 11/21 patients in the placebo group were alive.
Mean overall survival was 50.7 months in the Agaricus group
and 47.4 months in the placebo group (𝑃 = 0.93). Median
observation time was 48.0 months (𝑛 = 40).
3.8. Discussion. A significant increase of IL-1ra, IL-5, and IL-
7 serum levels was found in the Agaricus group compared
to placebo, albeit the genes for IL-5 and IL-7 were found
to be downregulated or unaltered, respectively, in the gene
expression analysis. Also, the gene for the proinflammatory
chemokine CCL2 (MCP-1) was found to be downregulated
in the Agaricus relative to the placebo group.
IL-1ra is a natural inhibitor of the proinflammatory
cytokine IL-1𝛽, which serves a modulator for a variety of
immune responses [30]. In particular, recombinant IL-1ra
(Anakinra) is used in the treatment of rheumatoid arthritis
and a variety of other autoimmune diseases [31, 32]. Elevated
levels of IL-1ra have been documented in several types of
cancer [33] including multiple myeloma, where it is asso-
ciated with an improved prognosis [34]. IL-1ra counteracts
IL-1𝛽, which stimulates the production of IL-6 by bone
marrow stroma cells. IL-6 is an important growth factor in
multiple myeloma [35]. In a clinical trial, treatment with
recombinant IL-1ra in patients with smoldering or indolent
multiple myeloma was associated with a decreased myeloma
proliferative rate [36]. On this background, the elevated levels
of IL-1ra found in patients treated with AndoSan in our study
may indicate a positive treatment effect of this product. This
is also in line with the finding of reduced expression of the
gene for the proinflammatory chemokine CCL2 (MCP-1).
The main role of IL-5 is to stimulate the production of
eosinophils [37]. It has recently been shown that eosinophils
can stimulate the growth of malignant plasma cells [38]. The
elevated levels of IL-5 found in the AndoSan group may
therefore be interpreted as a negative factor, although there
was an unaltered level of expression of the IL-5 gene. No
clinical study on the role of IL-5 in multiple myeloma has to
our knowledge been published.
IL-7 is a strong stimulator of both B-lymphocytes and T-
lymphocytes [39]. In patients with multiple myeloma treated
with high dose ofmelphalan with stem cell support, a gradual
rise in plasma levels of IL-6, IL-7, and IL-15 was noted in
aplasia, peaking on day +10 after infusion of hematopoietic
stem cells [40]. It has been suggested that these cytokines
may stimulate the proliferation of T cells in the autograft,
among them also specific antimyeloma T cells [40]. In this
perspective, the elevated IL-7 levels found in the AndoSan
group may be interpreted as a positive treatment effect.
In the harvested stem cell product, increased percentages
of regulatory T cells and plasmacytoid dendritic cells were
found.
Regulatory T cells (Tregs) constitute a subpopulation of
T cells, which modulates the immune system, maintains tol-
erance to self-antigens, and counteracts autoimmune disease
[41]. Elevated levels of Tregs in peripheral blood have been
found in both solid tumors and hematological malignancies
[42, 43], including multiple myeloma, in which Tregs play a
role in reducing immunosurveillance [44]. Excess of Tregs
might result from the influence of inflammatory cytokines
produced by tumor cells and tumor infiltrating lymphocytes
[44]. In a clinical study on multiple myeloma, levels of
Tregs were found to increase with increasing disease activity.
Furthermore, high levels of Tregswere found to reflect a lower
progression-free survival and total survival in patients treated
with conventional chemotherapy.However, a predictive value
for the levels of Tregs was not found in patients treated with
high dose chemotherapy and stem cell support in this study
[45]. In another study [46], the balance between suppressive
Tregs and proinflammatory Th-17 cells was found to show
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Figure 4: Ingenuity Pathway Analysis showing upregulation of genes in the HLA presentation pathway (symbols in red) in the Agaricus
group and downregulation of HLA genes (symbols in green) in the placebo group.
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a prognostic value for survival. In the present study, an
increased portion of Tregs in the leukapheresis product was
found in the Agaricus group compared to placebo. This may
be interpreted as an immunosuppressive factor with negative
impact on prognosis.
Plasmacytoid dendritic cells (pDC) stimulate both the
innate and the adaptive immune system and induce tolerance.
pDC levels are lower in multiple myeloma compared to
control, the lowest levels being found in the clinically most
advanced cases [47]. In the present study, proportions of
pDCs in the leukapheresis productwere higher in the patients
who received AndoSan compared to control, which may
suggest that AndoSan has a stimulatory effect, that is, a
positive treatment effect, in these patients.
Concerning the genetic analysis, an interesting pattern
was revealed by K-means clustering algorithm. In cluster
three, a number of immunoglobulin related genes (i.e., IGKC,
IgHV4-31, and IGKC) and genes related to Natural Killer
cells, Killer Immunoglobulin Receptors (i.e., KIR2DL3 and
KIR2DL4), were grouped together. These genes had a low
level of expression in the control group but were highly
expressed in the Agaricus group suggesting an immunomod-
ulatory effect of AndoSan (Figure 3). Furthermore, using the
Ingenuity analysis system, an upregulation of HLA genes
(Figure 4) and of the CD86 gene was found. In a previous
study, we have found an upregulation of CD86, CD83,
and CD80 on dendritic cells cultivated in the presence of
AndoSan [15]. In the proliferation assay, a dose dependent
inhibitory effect of AndoSan towards mouse myeloma cells
was found, starting at 1%. This indicates that AndoSan may
also have a direct antiproliferative effect on myeloma cells,
which may be clinically significant. In earlier studies an
inhibitory/tumoricidal effect of Agaricus has been reported
in fibrosarcoma [5, 9] and ovarian cancer [6] and in human
hepatocarcinoma [7] and leukemic cells [8].
A major difficulty in interpreting the results of this
study is the fact that the composition of AbM and thus
its presumed mechanism of action is at present unclear.
Originally, it has been claimed from the producer that
AndoSan contained 89% of carbohydrates, of which 𝛽-glucan
constituted 28% [20]. However, a pharmacological analysis,
which became publicly available after the completion of
our study, showed that the net carbohydrate content in this
product is considerably lower, that is, only 2%, corresponding
to 0.09% of 𝛽-glucan. According to this analysis, the majority
of the carbohydrates in this product consist of mono- and
oligosaccharides [48]. The main mechanism of action of
AndoSan may therefore be linked to other substances than
𝛽-glucans.
4. Conclusion
The study showed evidence of a number of immunomodulat-
ing effects of AndoSan, used as adjuvant therapy to high dose
of melphalan with autologous stem cell support in patients
with multiple myeloma, which possibly may have a clinical
significance. However, the results must be interpreted with
caution because of the restricted sample size of the study.
No statistically significant clinical impact of AndoSan was
detected, although trends for a longer median time to next
treatment (37.5 months versus 31.2 months) and a shorter
period of i.v. antibiotics (8.6 days versus 10.0 days) were noted
in the Agaricus group. Further investigations of the effect of
AndoSan in multiple myeloma in larger patient populations
with a sample size large enough to detect clinical differences
are needed in order to clarify whether AndoSan may have a
role in the treatment of this disease.
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